Amgen Inc. (BVMF:AMGN34)

Market Cap	1.08T +22.2%
Revenue (ttm)	202.42B +10.0%
Net Income	42.47B +88.5%
EPS	78.38 +88.2%
Shares Out	n/a
PE Ratio	25.43
Forward PE	17.11
Dividend	1.27 (1.81%)
Ex-Dividend Date	Nov 19, 2025

Volume	69
Average Volume	1,097
Open	68.68
Previous Close	68.68
Day's Range	68.68 - 70.07
52-Week Range	48.40 - 75.12
Beta	0.47
RSI	63.91
Earnings Date	Feb 3, 2026

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1980
• Employees: 28,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: AMGN34

Financial Performance

In 2025, Amgen's revenue was $36.75 billion, an increase of 9.95% compared to the previous year's $33.42 billion. Earnings were $7.71 billion, an increase of 88.53%.

Financial numbers in USD